Breast Cancer

Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.

An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.

In a discussion at IBC East, Heather McArthur, MD, highlighted how immunotherapy is being utilized for patients with early-stage breast cancer.

Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.

Heather McArthur, MD, spoke about the use of CDK4/6 inhibitors in the adjuvant setting for patients with HR+/HER2– breast cancer.

Patient-reported satisfaction was higher in patients with breast cancer treated with olanzapine vs those who underwent treatment with placebo.

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.

Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.